302 related articles for article (PubMed ID: 23443327)
21. Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?
Corallo C; Cheleschi S; Cutolo M; Soldano S; Fioravanti A; Volpi N; Franci D; Nuti R; Giordano N
Arthritis Res Ther; 2019 Jun; 21(1):152. PubMed ID: 31234888
[TBL] [Abstract][Full Text] [Related]
22. Effect of granulocyte macrophage-colony stimulating factor on extracellular matrix deposition by dermal fibroblasts from patients with scleroderma.
Postiglione L; Ladogana P; Montagnani S; di Spigna G; Castaldo C; Turano M; Bruno EM; Di Meglio F; Riccio A; Rossi G
J Rheumatol; 2005 Apr; 32(4):656-64. PubMed ID: 15801021
[TBL] [Abstract][Full Text] [Related]
23. Estradiol levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival.
Baker Frost D; Wolf B; Peoples C; Fike J; Silver K; Laffoon M; Medsger TA; Feghali-Bostwick C
Arthritis Res Ther; 2019 Apr; 21(1):85. PubMed ID: 30940202
[TBL] [Abstract][Full Text] [Related]
24. Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients.
Arakawa H; Jinnin M; Muchemwa FC; Makino T; Kajihara I; Makino K; Honda N; Sakai K; Fukushima S; Ihn H
Exp Dermatol; 2011 Sep; 20(9):764-6. PubMed ID: 21615510
[TBL] [Abstract][Full Text] [Related]
25. Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis.
Ichimura Y; Asano Y; Akamata K; Takahashi T; Noda S; Taniguchi T; Toyama T; Aozasa N; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
Arch Dermatol Res; 2014 May; 306(4):331-8. PubMed ID: 24292093
[TBL] [Abstract][Full Text] [Related]
26. Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis.
Avouac J; Clemessy M; Distler JH; Gasc JM; Ruiz B; Vacher-Lavenu MC; Wipff J; Kahan A; Boileau C; Corvol P; Allanore Y
Rheumatology (Oxford); 2011 Aug; 50(8):1494-504. PubMed ID: 21454305
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of serum soluble Tie1 levels in patients with systemic sclerosis.
Noda S; Asano Y; Aozasa N; Akamata K; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
Arch Dermatol Res; 2013 May; 305(4):325-31. PubMed ID: 23233281
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease.
Tomcik M; Zerr P; Palumbo-Zerr K; Storkanova H; Hulejova H; Spiritovic M; Kodet O; Stork J; Becvar R; Vencovsky J; Pavelka K; Filkova M; Distler JH; Senolt L
Rheumatology (Oxford); 2015 Dec; 54(12):2273-82. PubMed ID: 26231346
[TBL] [Abstract][Full Text] [Related]
29. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
Hamaguchi Y; Fujimoto M; Matsushita T; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
[TBL] [Abstract][Full Text] [Related]
30. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis.
Kawaguchi Y; Harigai M; Hara M; Fukasawa C; Takagi K; Tanaka M; Tanaka E; Nishimagi E; Kamatani N
J Rheumatol; 2002 Sep; 29(9):1877-83. PubMed ID: 12233882
[TBL] [Abstract][Full Text] [Related]
31. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha.
Chizzolini C; Parel Y; De Luca C; Tyndall A; Akesson A; Scheja A; Dayer JM
Arthritis Rheum; 2003 Sep; 48(9):2593-604. PubMed ID: 13130479
[TBL] [Abstract][Full Text] [Related]
32. Increased serum soluble CD40 levels in patients with systemic sclerosis.
Komura K; Fujimoto M; Matsushita T; Yanaba K; Kodera M; Kawasuji A; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2007 Feb; 34(2):353-8. PubMed ID: 17295440
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts.
Chizzolini C; Rezzonico R; Ribbens C; Burger D; Wollheim FA; Dayer JM
Arthritis Rheum; 1998 Nov; 41(11):2039-47. PubMed ID: 9811060
[TBL] [Abstract][Full Text] [Related]
34. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.
Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO
Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947
[TBL] [Abstract][Full Text] [Related]
35. Decreased secretion of MMP by non-lesional late-stage scleroderma fibroblasts after selection via activation of the apoptotic Fas-pathway.
Chabaud S; Corriveau MP; Grodzicky T; Senécal JL; Chartier S; Raymond Y; Moulin VJ
J Cell Physiol; 2011 Jul; 226(7):1907-14. PubMed ID: 21506121
[TBL] [Abstract][Full Text] [Related]
36. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts.
Chen Y; Shi-wen X; Eastwood M; Black CM; Denton CP; Leask A; Abraham DJ
Arthritis Rheum; 2006 Apr; 54(4):1309-16. PubMed ID: 16575856
[TBL] [Abstract][Full Text] [Related]
37. A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis.
Takahashi T; Asano Y; Noda S; Aozasa N; Akamata K; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
Br J Dermatol; 2015 Sep; 173(3):681-9. PubMed ID: 25781362
[TBL] [Abstract][Full Text] [Related]
38. Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts.
He Y; Tsou PS; Khanna D; Sawalha AH
Ann Rheum Dis; 2018 Aug; 77(8):1208-1218. PubMed ID: 29760157
[TBL] [Abstract][Full Text] [Related]
39. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.
Kim WU; Min SY; Cho ML; Hong KH; Shin YJ; Park SH; Cho CS
Arthritis Res Ther; 2005; 7(1):R71-9. PubMed ID: 15642145
[TBL] [Abstract][Full Text] [Related]
40. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
